• Corpus ID: 21856764

[The effect of carvedilol on enhanced adp-ribosylation and red blood cell membrane damage caused by free radicals].

  title={[The effect of carvedilol on enhanced adp-ribosylation and red blood cell membrane damage caused by free radicals].},
  author={Tam{\'a}s Habon and Eszter Szabados and G{\'a}bor K{\'e}sm{\'a}rky and R{\'o}bert Halmosi and Tibor Past and Bal{\'a}zs Sumegi and Kalman Toth},
  journal={Acta pharmaceutica Hungarica},
  volume={71 3},
OBJECTIVE Previous studies have reported that the beta and alpha adrenoceptor blocker carvedilol had unique protective effect on free radical induced myocardial injury. The aim of this study was to examine how carvedilol regulates ROI-mediated signaling and decreases RBC membrane damage in heart perfusion and rheological model. METHODS The ischemia-reperfusion induced oxidative cell damages, and changes in the intracellular signaling mediated by reactive oxygen species and peroxynitrite were… 

Cellular and molecular mechanisms of the enhanced survival benefits of the β I -adrenoceptor biased agonist, carvedilol, in diabetic cardiomyopathy with heart failure: a case report and literature review

The anti-oxidant carvedilol reduces cardiac catecholamine toxicity by inhibition of ROS-mediated upregulation of central RhoA and ROCK II kinase to decrease central sympathetic activation and baroreceptor imbalance while attenuating eNOS mRNA destabilisation.

The Role of Akt and Mitogen-Activated Protein Kinase Systems in the Protective Effect of Poly(ADP-Ribose) Polymerase Inhibition in Langendorff Perfused and in Isoproterenol-Damaged Rat Hearts

Evidence is provided for the first time that PARP inhibition beneficially modulates the cardiac Akt and MAPK signaling in ex vivo and in vivo ischemia-reperfusion models and it is proposed that this novel mechanism may contribute to the cardioprotective properties of PARP inhibitors.

The Role of β-Adrenergic Blockers in Parkinson’s Disease

β-Adrenergic blockade may have a significant role in PD; therefore, the characterization of β-adRenergic blockade in patients with PD is needed.

The Role of Beta-Adrenergic Receptor Blockers in Alzheimer’s Disease

The characterization of beta-adrenergic receptor blockade in patients with AD is needed because Behavioral symptoms, sex, or genetic factors, including Beta 2-adRenergic receptor variants, apolipoprotein E, and cytochrome P450 CYP2D6, may contribute to beta- adrenergic receptors blockade modulation in AD.